Conference report: Pembrolizumab plus lenvatinib meets dual primary endpoints versus chemotherapy in patients with advanced endometrial cancer following prior platinum-based chemotherapy in KEYNOTE-775/Study 309

In RCT (n=827), combination reduced risk of death by 38%, with median overall survival of 18.3 vs. 11.4 months with chemotherapy regardless of mismatch repair status; and risk of disease progression or death by 44% with a median progression-free survival of 7.2 vs. 3.8 months

SPS commentary:

KEYNOTE-775/Study 309 is the confirmatory trial for KEYNOTE-146/Study 111, which supported the FDA 2019 accelerated approval of the pembrolizumab plus lenvatinib combination for the treatment of patients with advanced endometrial carcinoma that is not MSI-H or dMMR, who have disease progression following prior systemic therapy and are not candidates for curative surgery or radiation.

Biospace Inc.